Results 151 to 160 of about 60,195 (236)

Radiation‐Associated Enteric‐Type Urethral Adenocarcinoma 20 Years After Prostate Brachytherapy: A Case Treated With Neoadjuvant Gemcitabine‐Cisplatin and Robot‐Assisted Radical Cystectomy

open access: yesIJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Brachytherapy is a widely accepted treatment for prostate cancer, in which subsequent radiation‐associated enteric‐type urethral adenocarcinoma is extremely rare. Case Presentation An 83‐year‐old man with a history of cholecystitis, appendicitis, and hyperlipidemia who had undergone brachytherapy 20 years earlier presented with ...
Yuki Tanaka   +6 more
wiley   +1 more source

Acute Cardiac Tamponade Following Enfortumab Vedotin Initiation in Metastatic Urothelial Carcinoma: Successful Rescue by Pericardial Fenestration

open access: yesIJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Enfortumab vedotin is a Nectin‐4‐directed antibody–drug conjugate approved for metastatic urothelial carcinoma. Cardiac adverse events such as pericardial effusion or tamponade associated with enfortumab vedotin are extremely rare. Case Presentation A 50‐year‐old man with metastatic UC developed chest pain and dyspnea 3 days after
Hiroto Akamatsu   +7 more
wiley   +1 more source

Two Cases of Bilateral Ureteral Metastases From Prostate Cancer Initially Presenting With Postrenal Acute Kidney Injury

open access: yesIJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Although prostate‐specific antigen (PSA) screening has facilitated early detection of prostate cancer, approximately 5% of patients still present with distant metastases at diagnosis. Ureteral metastasis from prostate cancer is extremely rare.
Hiroshi Ushida   +3 more
wiley   +1 more source

Long‐term outcomes following a 5‐year recurrence‐free interval in non‐muscle‐invasive bladder cancer

open access: yesBJU International, Volume 138, Issue 1, Page 125-132, July 2026.
Objective To describe the recurrence and progression trends of non‐muscle‐invasive bladder cancer (NMIBC) during a 14‐year period in Denmark between 2009 and 2022. Furthermore, to evaluate the risk of late recurrence with or without progression in patients who initially experience a 5‐year recurrence‐free interval (RFI).
Peter B. Hjort   +2 more
wiley   +1 more source

A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancer

open access: yesBJU International, Volume 138, Issue 1, Page 144-155, July 2026.
Objectives To establish a UK consensus vision of a standardised genomic testing pathway in unresectable/metastatic urothelial cancer (mUC) with clear roles and responsibilities for multidisciplinary team (MDT) members and molecular pathology laboratory teams, and to agree how the pathway must evolve to accommodate emerging innovations.
Syed A. Hussain   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy